Lene Ryom

Lene Ryom serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, based at Rigshospitalet (Copenhagen University Hospital). She leads the pharmacovigilance substudy of the RESPOND Cohort Consortium, an international research initiative focused on monitoring adverse events associated with antiretroviral therapy for HIV.

Dr. Ryom's research primarily investigates the long-term health outcomes of people living with HIV, with particular emphasis on metabolic complications, cardiovascular risks, and bone health associated with modern antiretroviral regimens. Her work examines how different drug classes, particularly integrase strand transfer inhibitors and tenofovir alafenamide, affect body mass index, diabetes risk, hypertension, dyslipidemia, and fracture incidence. She employs large-scale observational data from multiple international HIV cohort studies to identify potential safety concerns and optimize treatment strategies.

Her recent publication record demonstrates significant contributions to HIV clinical research, with numerous articles in high-impact journals including Clinical Infectious Diseases and The Lancet. Her work spans clinical HIV management, cardiovascular disease prevention in HIV populations, cancer risk assessment, and the development of guidance for statin use in people with HIV. The RESPOND study, which she chairs, receives funding from Gilead Sciences, ViiV, and BMS, though she emphasizes the independence of the research agenda and conduct, which is overseen by an international scientific steering committee.

Dr. Ryom actively collaborates with major HIV research networks including the D:A:D Study Group and the Swiss HIV Cohort Study, contributing to the global understanding of HIV treatment outcomes and safety profiles. Her research has been referenced in clinical guidelines and picked up by multiple news outlets, demonstrating its relevance to both clinical practice and public health discourse.